CanSino Biologics Inc. (6185.HK)
HKD 33.5
(-1.33%)
HKD 33.5
(-1.33%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.2 Billion CNY | -4.68% |
| 2022 | 1.26 Billion CNY | 5.04% |
| 2021 | 1.2 Billion CNY | 169.93% |
| 2020 | 445.06 Million CNY | 117.95% |
| 2019 | 204.2 Million CNY | 34.04% |
| 2018 | 152.35 Million CNY | 101.51% |
| 2017 | 75.6 Million CNY | 39.07% |
| 2016 | 54.36 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 180.57 Million CNY | 12.03% |
| 2024 Q1 | 173.77 Million CNY | -50.84% |
| 2023 Q2 | 324.05 Million CNY | 38.57% |
| 2023 Q1 | 233.85 Million CNY | -32.66% |
| 2023 FY | 1.2 Billion CNY | -4.68% |
| 2023 Q4 | 353.47 Million CNY | 21.26% |
| 2023 Q3 | 291.5 Million CNY | -10.04% |
| 2022 Q3 | 396.71 Million CNY | 158.0% |
| 2022 Q4 | 347.25 Million CNY | -12.47% |
| 2022 Q1 | 251.04 Million CNY | -26.76% |
| 2022 Q2 | 153.76 Million CNY | -38.75% |
| 2022 FY | 1.26 Billion CNY | 5.04% |
| 2021 Q4 | 342.76 Million CNY | 81.44% |
| 2021 FY | 1.2 Billion CNY | 169.93% |
| 2021 Q1 | 283.65 Million CNY | 7.53% |
| 2021 Q3 | 188.91 Million CNY | -46.76% |
| 2021 Q2 | 354.81 Million CNY | 25.09% |
| 2020 Q3 | 80.12 Million CNY | -6.41% |
| 2020 FY | 445.06 Million CNY | 117.95% |
| 2020 Q2 | 85.61 Million CNY | 98.23% |
| 2020 Q1 | 43.18 Million CNY | -37.22% |
| 2020 Q4 | 263.78 Million CNY | 229.22% |
| 2019 Q3 | 50.02 Million CNY | 19.76% |
| 2019 FY | 204.2 Million CNY | 34.04% |
| 2019 Q2 | 41.76 Million CNY | -17.74% |
| 2019 Q1 | 50.77 Million CNY | 1.25% |
| 2019 Q4 | 68.79 Million CNY | 37.53% |
| 2018 Q1 | 29.64 Million CNY | 5361.54% |
| 2018 Q3 | 50.14 Million CNY | 69.17% |
| 2018 Q4 | 50.14 Million CNY | 0.0% |
| 2018 FY | 152.35 Million CNY | 101.51% |
| 2018 Q2 | 29.64 Million CNY | 0.0% |
| 2017 Q2 | 197.25 Thousand CNY | 0.0% |
| 2017 Q4 | 542.75 Thousand CNY | 0.0% |
| 2017 FY | 75.6 Million CNY | 39.07% |
| 2017 Q1 | 197.25 Thousand CNY | 0.0% |
| 2016 Q1 | 108.5 Thousand CNY | 0.0% |
| 2016 FY | 54.36 Million CNY | 0.0% |
| 2016 Q4 | 197.25 Thousand CNY | 0.0% |
| 2016 Q2 | 108.5 Thousand CNY | 0.0% |
| 2015 Q4 | 108.5 Thousand CNY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 24.42 Million HKD | -4825.02% |
| Grand Pharmaceutical Group Limited | 3.86 Billion HKD | 68.843% |
| Extrawell Pharmaceutical Holdings Limited | 35.52 Million HKD | -3285.839% |
| Wai Yuen Tong Medicine Holdings Limited | 353.93 Million HKD | -239.863% |
| Qianhai Health Holdings Limited | 17.1 Million HKD | -6933.604% |
| Lee's Pharmaceutical Holdings Limited | 590.99 Million HKD | -103.537% |
| Essex Bio-Technology Limited | 1.22 Billion HKD | 2.122% |
| Tongfang Kontafarma Holdings Limited | 503.46 Million HKD | -138.923% |
| PuraPharm Corporation Limited | 216.62 Million HKD | -455.275% |
| SSY Group Limited | 1.98 Billion HKD | 39.271% |
| JBM (Healthcare) Limited | 163.87 Million HKD | -634.023% |
| Jacobson Pharma Corporation Limited | 287.34 Million HKD | -318.615% |
| China Resources Pharmaceutical Group Limited | 29.35 Billion HKD | 95.902% |